Strides Pharma Science zooms as its arm gets USFDA`s approval for Icosapent Ethyl Capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Strides Pharma Science is currently trading at Rs. 526.00, up by 27.35 points or 5.48% from its previous closing of Rs. 498.65 on the BSE.
The scrip opened at Rs. 516.10 and has touched a high and low of Rs. 538.65 and Rs. 506.25 respectively. So far 122722 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 538.65 on 15-Sep-2023 and a 52 week low of Rs. 268.40 on 21-Mar-2023.
Last one week high and low of the scrip stood at Rs. 538.65 and Rs. 473.45 respectively. The current market cap of the company is Rs. 4744.73 crore.
The promoters holding in the company stood at 28.07%, while Institutions and Non-Institutions held 36.72% and 35.21% respectively.
Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global has received approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vascepa of Amarin. The Icosapent Ethyl Capsules has a market size of around $1.3 billion as per IQVIA. The product will be manufactured at the Company’s facility in Bengaluru.
The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which more than 230 ANDAs have been approved. The company has set a target to launch around 60 new products over three years in the US.
